Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00822094 · ClinicalTrials.gov registry record · Phase 2
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT00822094 is a Phase 2 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 126 participants.
The verdict
NCT00822094, a Phase 2 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens. The study compares the investigational product CPX-351 vs the standard intensive salvage treatment for first relapse AML patients.
Interventions
- DRUG CPX-351
- DRUG Intensive Salvage Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00822094
The ClinicalTrials.gov registry entry for NCT00822094 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CPX-351 is the first listed.
NCT00822094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00822094 about?
NCT00822094 is a clinical study titled "Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)". The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens. The study compares the investigational product CPX-351 vs the standard intensive salvage treatment for first re...
What is the current status of trial NCT00822094?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2009-02. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00822094?
The interventions under investigation include: CPX-351 (DRUG), Intensive Salvage Therapy (DRUG).
Who is sponsoring clinical trial NCT00822094?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.